Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age22+
SponsorEMVision Medical Devices Ltd

About this trial

The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.

EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults ≥22 years of age

Observable acute neurological deficit suspected to be stroke and within 24 hours of symptom onset

The use of the EMVision emu™ Brain Scanner will not delay the treatment of the patient

CT or MRI brain imaging following clinical evaluation per standard of care

Disqualifiers

Has received treatment for current (suspected) stroke event prior to initial CT/MRI scan OR EMVision emu™ Brain Scanner scan (such as thrombolysis)

In-patient for a neurological condition prior to suspected stroke onset

In-patient in intensive care unit prior to suspected stroke onset

Contraindication to neuroimaging, such as a contrast allergy or other condition that prohibits CT, MRI and/or angiography

Trial population

300 subjects across two study arms

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Brain Scan

    Diagnostic test

    The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head. The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues.

Treatment groups

300 Participants
are divided into 2 treatment groups
Group A: Intracranial Haemorrhage Group A1 intervention
Group B: Other Group B1 intervention

Trial outcomes

Primary outcomes

1

Demonstrate haemorrhage detection sensitivity >80% and specificity >80%

Time frame
<30 minutes from acute baseline CT/MRI

Secondary outcomes

1

Demonstrate the time to complete an emu™ Brain Scan is <15 minutes

Time frame
<30 minutes from acute baseline CT/MRI
2

Evaluate safety of the device

Time frame
<30 minutes from acute baseline CT/MRI
3

Evaluate usability of the device

Time frame
<30 minutes from acute baseline CT/MRI
4

Evaluate device deficiencies

Time frame
<30 minutes from acute baseline CT/MRI

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.